Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Influenza Candidate Vaccine GSK2340274A
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 09 Apr 2011 New trial record